Dania Therapeutics ApS: Financial statements 2023
CVR: 42523925
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Dania Therapeutics ApS (CVR 42523925) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -9,191,440 and a net result of DKK -8,721,963. Equity in the 2023 report amounted to DKK -1,226,884. The company had 1 employee in the financial year.
- Revenue
- DKK 0
- Gross Profit
- DKK -9,191,440
- Profit/Loss
- DKK -8,721,963
- Equity
- DKK -1,226,884
- Total Assets
- DKK 15,063,137
- Employees
- 1
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of November 1, 2023, Michael Manchuan Li has joined the board of directors of Dania Therapeutics ApS.
As of November 1, 2023, Lars Michael Wood has left the board of directors of Dania Therapeutics ApS.
Dania Therapeutics ApS has published its interim report for the period July 1, 2021 to December 31, 2022.
About Dania Therapeutics ApS
Dania Therapeutics ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Karin Absalonsen. The board consists of Karin Absalonsen (chair), Kristian Helin and Michael Manchuan Li. The company is owned by Kristian Helin, Hannibal Innovation ApS and Vernalis (R&D) Limited. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -3,390,139 and a net result of DKK -5,039,754 compared with DKK -9,556,855 the year before. Equity in the 2025 report amounted to DKK -15,413,086.